K2M Group Holdings Inc (NASDAQ:KTWO) had its price objective cut by Needham & Company LLC from $27.00 to $26.00 in a research note published on Thursday. They currently have a strong-buy rating on the medical device company’s stock.

A number of other equities research analysts also recently issued reports on KTWO. Oppenheimer Holdings, Inc. reissued a buy rating on shares of K2M Group Holdings in a research note on Tuesday, July 11th. Cowen and Company restated a buy rating and issued a $26.00 price objective on shares of K2M Group Holdings in a report on Wednesday, July 19th. BidaskClub upgraded shares of K2M Group Holdings from a hold rating to a buy rating in a report on Wednesday, July 19th. Royal Bank Of Canada restated a buy rating and issued a $26.00 price objective on shares of K2M Group Holdings in a report on Thursday, July 20th. Finally, Zacks Investment Research upgraded shares of K2M Group Holdings from a sell rating to a hold rating in a report on Saturday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. K2M Group Holdings currently has a consensus rating of Buy and an average target price of $25.00.

K2M Group Holdings (NASDAQ KTWO) traded down $0.16 on Thursday, hitting $18.93. The stock had a trading volume of 357,739 shares, compared to its average volume of 773,942. The company has a current ratio of 3.06, a quick ratio of 1.91 and a debt-to-equity ratio of 0.29.

K2M Group Holdings (NASDAQ:KTWO) last released its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. K2M Group Holdings had a negative net margin of 13.51% and a negative return on equity of 13.50%. K2M Group Holdings’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm posted ($0.19) earnings per share. analysts predict that K2M Group Holdings will post -0.83 EPS for the current year.

WARNING: “K2M Group Holdings Inc (KTWO) Given New $26.00 Price Target at Needham & Company LLC” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/k2m-group-holdings-inc-ktwo-given-new-26-00-price-target-at-needham-company-llc/1678699.html.

In other K2M Group Holdings news, CFO Gregory S. Cole sold 39,357 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $23.37, for a total transaction of $919,773.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Philip Md Kostuik sold 1,332 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $23.30, for a total transaction of $31,035.60. Following the transaction, the insider now owns 200,629 shares of the company’s stock, valued at approximately $4,674,655.70. The disclosure for this sale can be found here. Insiders have sold a total of 44,129 shares of company stock valued at $1,033,644 in the last quarter. 5.80% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its holdings in K2M Group Holdings by 82.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 211,585 shares of the medical device company’s stock worth $5,154,000 after acquiring an additional 95,548 shares in the last quarter. Artemis Investment Management LLP lifted its position in shares of K2M Group Holdings by 255.4% during the 2nd quarter. Artemis Investment Management LLP now owns 316,703 shares of the medical device company’s stock worth $7,716,000 after buying an additional 227,582 shares during the last quarter. Schroder Investment Management Group lifted its position in shares of K2M Group Holdings by 1.6% during the 2nd quarter. Schroder Investment Management Group now owns 1,560,340 shares of the medical device company’s stock worth $37,401,000 after buying an additional 24,671 shares during the last quarter. Credit Suisse AG lifted its position in shares of K2M Group Holdings by 9.8% during the 1st quarter. Credit Suisse AG now owns 212,672 shares of the medical device company’s stock worth $4,360,000 after buying an additional 18,931 shares during the last quarter. Finally, Tocqueville Asset Management L.P. lifted its position in shares of K2M Group Holdings by 60.4% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 22,450 shares of the medical device company’s stock worth $547,000 after buying an additional 8,450 shares during the last quarter. Institutional investors own 99.13% of the company’s stock.

K2M Group Holdings Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.